Reproductive Health

Reproductive Health UK Medical PG Question 1: A 26-year-old woman presents with amenorrhea, galactorrhea, and headaches. Visual field defects are noted. What is the appropriate initial treatment?

• A. Transsphenoidal surgery
• B. Cabergoline (Correct Answer)
• C. Radiotherapy
• D. Observation
• E. Bromocriptine

Reproductive Health Explanation: ***Cabergoline***- **Cabergoline** is the preferred first-line treatment for suspected **prolactinomas** (indicated by amenorrhea and galactorrhea), regardless of tumor size, due to its high efficacy in normalizing prolactin levels and shrinking the tumor.- This drug, a **dopamine agonist**, can rapidly reduce tumor volume, often resolving the mass effect symptoms like headaches and **visual field defects**, which are crucial to address immediately.*Transsphenoidal surgery*- Surgery is generally reserved for patients who are intolerant of or unresponsive to maximal **dopamine agonist** therapy, or for specific tumor types (e.g., highly cystic).- Given the typical response rates of prolactinomas to medical therapy, surgery is not the appropriate **initial** treatment.*Radiotherapy*- Radiotherapy is typically reserved as a **tertiary treatment** for aggressive or malignant prolactinomas that have failed to respond to both dopamine agonists and surgical resection.- It carries risks of long-term pituitary dysfunction and damage to surrounding **neural structures**, making it inappropriate for initial management.*Observation*- Observation is only appropriate for asymptomatic patients with **microprolactinomas** (less than 10 mm) without mass effect or desire for fertility.- Since this patient has significant symptoms (galactorrhea, amenorrhea) and signs of mass effect (**visual field defects**), immediate intervention is necessary.*Bromocriptine*- Bromocriptine is also a **dopamine agonist** effective for prolactinomas but is generally considered a second-line option to Cabergoline.- **Cabergoline** is preferred due to its higher efficacy, longer half-life (allowing less frequent dosing), and better patient tolerability (fewer **gastrointestinal side effects**).

Reproductive Health UK Medical PG Question 2: A 43-year-old woman presents with fatigue, weight gain, and cold intolerance. TSH is 22 mU/L, free T4 is low. Anti-TPO antibodies are positive. She is trying to conceive. What is the TSH target?

• A. $< 1.0 \mathrm{mU} / \mathrm{L}$
• B. $< 2.5 \mathrm{mU} / \mathrm{L}$ (Correct Answer)
• C. $< 4.0 \mathrm{mU} / \mathrm{L}$
• D. $< 6.0 \mathrm{mU} / \mathrm{L}$
• E. $< 10.0 \mathrm{mU} / \mathrm{L}$

Reproductive Health Explanation: ***< 2.5 \mathrm{mU} / \mathrm{L}$*** - For women with **hypothyroidism** who are trying to conceive or are in the first trimester of pregnancy, the recommended TSH target is generally **< 2.5 mU/L** to ensure optimal maternal and fetal outcomes. - Achieving this target helps to reduce the risk of **infertility**, **miscarriage**, and adverse pregnancy complications such as **preterm birth** and **gestational hypertension**, while also supporting proper fetal neurodevelopment. *$< 1.0 \mathrm{mU} / \mathrm{L}$* - This target is generally considered **too stringent** and may lead to **over-treatment** with levothyroxine, potentially inducing iatrogenic hyperthyroidism symptoms. - While very low TSH can be observed, it is not the standard recommendation for preconception in hypothyroidism and could be unnecessarily aggressive. *$< 4.0 \mathrm{mU} / \mathrm{L}$* - While a TSH of < 4.0 mU/L might be acceptable for non-pregnant adults with hypothyroidism, it is **insufficient** for women trying to conceive or in early pregnancy. - Higher TSH levels during the preconception period and early pregnancy are associated with increased risks for both the mother and the fetus, necessitating a tighter TSH control. *$< 6.0 \mathrm{mU} / \mathrm{L}$* - This TSH target is significantly **too high** for a woman attempting to conceive and is typically considered for adults with **subclinical hypothyroidism** (TSH 4-10 mU/L) who are **not pregnant**. - Maintaining TSH at this level during pregnancy substantially increases the risk of **adverse obstetric outcomes** and potential cognitive deficits in the offspring. *$< 10.0 \mathrm{mU} / \mathrm{L}$* - A TSH target of < 10.0 mU/L is far **too liberal** and would mean the patient remains **frankly hypothyroid** in the context of trying to conceive or during pregnancy. - This target would not adequately address the patient's severe hypothyroid symptoms nor mitigate the significant risks to successful conception and healthy pregnancy progression.

Reproductive Health UK Medical PG Question 3: A 34-year-old woman presents with recurrent miscarriages and a history of DVT. Blood tests show prolonged APTT not correcting with mixing studies, and positive anticardiolipin antibodies. What is the most likely diagnosis?

• A. Factor V Leiden
• B. Protein C deficiency
• C. Antiphospholipid syndrome (Correct Answer)
• D. Lupus anticoagulant
• E. Von Willebrand disease

Reproductive Health Explanation: ***Antiphospholipid syndrome*** - This syndrome is defined by recurrent **venous or arterial thrombosis** (DVT) and/or **pregnancy morbidity** (recurrent miscarriages), occurring in the presence of specific antiphospholipid antibodies. - The laboratory findings of positive **anticardiolipin antibodies** and a prolonged **APTT** (suggestive of lupus anticoagulant, an inhibitory antibody) that does not correct upon mixing strongly confirm the diagnosis of APS. *Factor V Leiden* - This condition is the most common inherited thrombophilia, characterized by resistance to cleavage by **Activated Protein C (APC)**, leading to increased clot risk. - While it causes thrombosis (like DVT), it does not cause the autoantibody profile (anticardiolipin) or the characteristic uncorrectable **APTT** observed. *Protein C deficiency* - This is an inherited thrombophilia resulting from insufficient levels of the anticoagulant Protein C, leading to uncontrolled coagulation. - It typically causes thrombosis but is not associated with obstetrical complications like **recurrent miscarriages** or the presence of **anticardiolipin antibodies**. *Lupus anticoagulant* - This is one of the specific antiphospholipid antibodies that define APS (causing the prolonged non-correcting **APTT** finding). - While present in this patient, it is a *laboratory criterion* for Antiphospholipid Syndrome (the definitive clinical diagnosis), which encompasses both the antibodies and the clinical events (DVT and miscarriages). *Von Willebrand disease* - This is the most common inherited **bleeding disorder**, caused by deficiency or dysfunction of **von Willebrand factor** (vWF). - It is characterized by mucocutaneous bleeding symptoms and is a disorder of **hemostasis**, not a thrombotic condition associated with DVT or recurrent miscarriages.

Reproductive Health UK Medical PG Question 4: A 54-year-old woman who had a total abdominal hysterectomy with conservation of ovaries for fibroid-related menorrhagia 6 years ago presents with a 12-month history of troublesome vasomotor symptoms, mood disturbance, and poor concentration affecting her work as a teacher. She also reports reduced libido which is causing relationship difficulties. She has no other medical history, BMI is 24 kg/m², and she does not smoke. Her blood pressure is 118/76 mmHg. What is the most appropriate HRT regimen to address all her symptoms?

• A. Transdermal estradiol patches 50 mcg twice weekly
• B. Oral estradiol 2 mg daily plus testosterone supplementation
• C. Transdermal estradiol patches plus oral micronised progesterone
• D. Tibolone 2.5 mg daily
• E. Transdermal estradiol patches with trial of testosterone supplementation if symptoms persist (Correct Answer)

Reproductive Health Explanation: ***Transdermal estradiol patches with trial of testosterone supplementation if symptoms persist*** - **Transdermal estradiol** is the first-line treatment for vasomotor symptoms, mood disturbance, and poor concentration in postmenopausal women, offering a lower **thromboembolic risk** compared to oral therapy by bypassing first-pass metabolism. - For **reduced libido**, guidelines recommend optimizing **estrogen levels** initially. If sexual dysfunction persists after 3-6 months of adequate estrogenization, a trial of **testosterone supplementation** is indicated to address this specific symptom. *Transdermal estradiol patches 50 mcg twice weekly* - While **transdermal estradiol** effectively manages **vasomotor symptoms** and cognitive issues, this option does not explicitly account for the patient's persistent **low libido**. - It overlooks the recommended step of considering **testosterone supplementation** if sexual desire issues are not resolved with estrogen alone. *Oral estradiol 2 mg daily plus testosterone supplementation* - **Oral estrogen** carries a higher risk of **venous thromboembolism (VTE)** and may not be the optimal choice for a low-risk woman when a transdermal option is available. - Initiating **testosterone** concurrently with initial HRT is generally not recommended; it's typically considered only after adequate **estrogenization** has failed to improve libido. *Transdermal estradiol patches plus oral micronised progesterone* - This patient has undergone a **total abdominal hysterectomy**, meaning she no longer has a uterus, and therefore does not require **progesterone** for endometrial protection. - The addition of **progesterone** in a woman without a uterus is unnecessary and can introduce additional side effects without benefit. *Tibolone 2.5 mg daily* - **Tibolone** has estrogenic, progestogenic, and **androgenic properties**, which could potentially address libido; however, it is not typically the first-line HRT, especially for multiple symptoms where a standard estrogen-progestogen (or estrogen-only) regimen is usually preferred. - It is associated with an increased risk of **stroke** in women over 60 years of age, making transdermal estradiol a generally safer initial choice.

Reproductive Health UK Medical PG Question 5: A 41-year-old parous woman requests contraception following the birth of her third child 4 weeks ago. She is not breastfeeding and is considering the combined oral contraceptive pill, which she used successfully between her previous pregnancies. She had an uncomplicated vaginal delivery with estimated blood loss of 400ml. She is a non-smoker with BMI of 26 kg/m² and no medical history of note. According to UKMEC criteria, when can she safely commence the combined oral contraceptive pill?

• A. At 3 weeks postpartum
• B. At 2 weeks postpartum
• C. Immediately, as she is not breastfeeding
• D. At 6 weeks postpartum (Correct Answer)
• E. At 12 weeks postpartum

Reproductive Health Explanation: ***At 6 weeks postpartum*** - In non-breastfeeding women without additional risk factors, the **combined oral contraceptive pill (COCP)** is classified as **UKMEC 2** (benefits outweigh risks) or UKMEC 1 only after **6 weeks postpartum**. - The postpartum period is associated with a significantly increased risk of **venous thromboembolism (VTE)**, which remains elevated until 6 weeks; starting COCP earlier carries an **unacceptable health risk**. *At 3 weeks postpartum* - Starting COCP between **21 days and 6 weeks** postpartum in non-breastfeeding women is classified as **UKMEC 3**, meaning the risks generally outweigh the benefits. - Although the absolute risk of VTE begins to decline after 3 weeks, it is still considered too high to routinely recommend **estrogen-containing** methods. *At 2 weeks postpartum* - Prior to **21 days (3 weeks)** postpartum, the use of COCP is classified as **UKMEC 4**, indicating an unacceptable health risk due to the peak in **hypercoagulability**. - Women are advised to use **progestogen-only** methods or barrier methods if contraception is required this early in the puerperium. *Immediately, as she is not breastfeeding* - Immediate initiation is contraindicated because the **prothrombotic state** of pregnancy does not resolve instantly upon delivery, regardless of breastfeeding status. - The classification for using COCP before 21 days is **UKMEC 4**, even in the absence of other risk factors like smoking or high BMI. *At 12 weeks postpartum* - Delaying initiation until **12 weeks** is unnecessary for this patient as she is a **non-smoker** with a normal BMI and no other VTE risk factors. - By 6 weeks, the VTE risk typically returns to baseline, making it safe to prescribe the pill according to **UKMEC guidelines**.

Reproductive Health Flashcard 1 of 5

Question: The average onset age for menopause is _____ years

Answer: 51

Reproductive Health Flashcard 2 of 5

Question: What contraceptive methods increase the risk of ectopic pregnancy if pregnancy occurs? _____

Answer: IUD, IUS, Progesterone only pill

Reproductive Health Flashcard 3 of 5

Question: _____ is the loss of ovarian follicular activity between the ages of 40 to 44 years

Answer: Early menopause

Reproductive Health Flashcard 4 of 5

Question: Anti-D prophylaxis should be given to women who are _____ and are having an abortion after 10+0 weeks' gestation

Answer: rhesus D negative

Reproductive Health Flashcard 5 of 5

Question: _____ is a risk factor for Ectopic Pregnancy

Answer: Endometriosis